Overview

Study of Busulfan, Etoposide, Cytarabine, and Melphalan (BuEAM) Conditioning for Autologous Stem Cell Transplantation (ASCT) to Treat B Cell Lymphoma Except for Diffuse Large B Cell Lymphoma

Status:
Unknown status

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy and toxicity of busulfan, etoposide, cytarabine and melphalan (BuEAM) as a conditioning for autologous stem cell transplantation in patients with non-Hodgkin lymphoma.

Phase:

Phase 2

Details

Lead Sponsor:

Seoul National University Hospital

Collaborators:

Asan Medical Center
Inje University
Severance Hospital
Ulsan University Hospital

Treatments:

Busulfan
Cytarabine
Etoposide
Etoposide phosphate
Melphalan